GeneDx Holdings (WGS) Free Cash Flow (2020 - 2026)

GeneDx Holdings (WGS) has 7 years of Free Cash Flow data on file, last reported at -$38.3 million in Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$38.3 million, down 579.94% year-over-year; the trailing twelve-month figure through Mar 2026 was -$19.3 million (down 208.94% YoY), and the FY2025 annual result was $27.0 million, up 186.81% from the prior year.
• Free Cash Flow declined to -$38.3 million in Q1 2026 per WGS's latest filing, from $5.3 million in the prior quarter.
• Over five years, Free Cash Flow peaked at $8.0 million in Q1 2025 and troughed at -$92.1 million in Q3 2022.
• A 5-year average of -$31.9 million and a median of -$28.8 million in 2023 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2025 and 2026: Free Cash Flow jumped 258.55% in 2025, then slumped 579.94% in 2026.
• A 5-year view of Free Cash Flow shows it stood at -$58.2 million in 2022, then surged by 50.53% to -$28.8 million in 2023, then surged by 88.39% to -$3.3 million in 2024, then jumped by 258.55% to $5.3 million in 2025, then tumbled by 823.89% to -$38.3 million in 2026.
• Business Quant data shows WGS's Free Cash Flow at -$38.3 million in Q1 2026, $5.3 million in Q4 2025, and $6.8 million in Q3 2025.